It will produce a comprehensive range of dosage forms including tablets, hard gelatin capsules, liquids, injectables, topicals, and beta-lactam products
Acquisition expands Novo Nordisk’s leadership in obesity-related comorbidities and metabolic diseases
Lupin's partnership program is designed to foster collaborations with companies looking to extend their product lifecycles
It represents a 30% increase in the company’s production capacity and introduces a segment dedicated to highly potent active ingredients
The new Houston site, Lilly's eighth U.S. manufacturing facility announced since 2020, will focus on domestic production of small molecule synthetic medicines
This marks the first of four new U.S. manufacturing sites that Lilly plans to announce this year
Drug Hunter is already relied upon by researchers at more than 200 leading organizations, including Eli Lilly, Biogen, Merck KGaA, Isomorphic Labs, Deerfield Management
Four FDA-approved products strengthen portfolio and reaffirm commitment to global reach
Subscribe To Our Newsletter & Stay Updated
